Cognitive Testing Study in Adults with Small-Cell and Non-Small-Cell Lung Cancer up to Age 70

What this Trial Is About

Researchers are investigating how lung cancer and its treatments may affect thinking and memory in patients with both small-cell lung cancer SCLC and non-small-cell lung cancer NSCLC. This observational study aims to understand the occurrence of cognitive impairment during the first year after patients join the study. The European Institute of Oncology is leading this research to better understand cognitive changes in lung cancer patients. The study includes patients diagnosed with lung cancer across all stages I to IV. There are no drug treatments or interventions involved since this is an observational study, meaning researchers will monitor and assess participants without giving any new treatments. Participants will be observed and evaluated during the first year after enrollment to track cognitive changes. Participants will undergo comprehensive neuropsychological assessments to measure thinking and memory abilities at different times over one year. Researchers will also look for risk factors that might affect cognitive function in lung cancer patients. The study excludes patients with brain metastases, brain radiotherapy, or other neurological or psychiatric disorders. The total time of involvement is up to 12 months, during which participants will complete cognitive tests and other assessments.

Cognitive Screening in Lung Cancer Patients